Itọju Ẹdọfóró Akàn Aláìṣiṣẹ́ 2026: TIL Tuntun & Awọn Ipinnu Ni pato

irohin

Irohin

Itọju Ẹdọfóró Akàn Aláìṣiṣẹ́ 2026: TIL Tuntun & Awọn Ipinnu Ni pato

Akoonu Awọn Iyipada Paradigm ni Itọju Ẹdọfóró Akàn Aiṣiṣẹ Ailoye Tumor-Infiltrating Lymphocyte (TIL) Therapy Bispecific Antibodies: The Dual-Target Approach Comparative Analysis of Eme...

04-09-2026

Itọju Ẹdọfóró akàn loorekoore 2026: Awọn ilọsiwaju Tuntun & Awọn Itọsọna Tuntun

Oye Akoonu Loorekoore Akàn Ẹdọfóró ni 2026 Titun Awọn Itọsọna NCCN fun Loorekoore Awọn Itọju Arun Akàn Ẹdọfóró Loorekoore fun Awọn ilana Akàn Lung Loorekoore fun EGFR-Mutant Recu…

04-09-2026

Itoju Akàn Ẹdọfóró Indolent 2026: Awọn Ilana Tuntun fun Iwalaaye Igba pipẹ

Oye Akoonu Indolent Akàn Ẹdọfóró ni 2026 Yipada Paradigm: Lati Iṣẹ abẹ Lẹsẹkẹsẹ si Iwoye Iṣiṣẹ Iṣeduro Awọn aṣayan Iṣẹ-abẹ Invasive Kere fun Awọn Egbo Ilọsiwaju ti o farahan T…

04-09-2026

Ipele 2A Itoju Akàn Ẹdọfóró 2026: Data ELCC Tuntun lori Itọju ailera Neo-Adjuvant

Oye Akoonu Ipele 2A Akàn Ẹdọfóró Ẹdọfóró Ẹdọgbọn Kekere 2026 ELCC Breakthroughs ni Neo-Adjuvant Strategies Itọju Awọn Itọju Iwakọ fun Ipele Iyipada Iwakọ 2A Iṣayẹwo Iṣalaye Akàn Ẹdọfóró ti Trea...

04-09-2026

Itoju Itọju Ẹdọfóró Ẹdọfóró Ipele Kekere 2026: Iza-bren Tuntun & Tarlatamab Breakthroughs

Akoonu Itankalẹ ti Ipele Itọju Ẹdọfóró Ẹdọfóró Ipele Kekere Iza-bren: Iyipada Paradigm ni Bispecific ADC Therapy Tarlatamab ati Dide ti T-Cell Olukoni Aabo ati Ifarada ni...

04-08-2026

Itọju Ẹdọfóró akàn loorekoore 2026: Awọn ilọsiwaju Tuntun & Awọn Itọsọna Tuntun

Oye Akoonu Loorekoore Akàn Ẹdọfóró ni 2026 Titun Awọn Itọsọna NCCN fun Loorekoore Awọn Itọju Arun Akàn Ẹdọfóró Loorekoore fun Awọn ilana Akàn Lung Loorekoore fun EGFR-Mutant Recu…

04-08-2026
Ile
Awọn ọran aṣoju
Nipa re
Pe wa

Jọwọ fi ifiranṣẹ silẹ fun wa